Jan 22, 2008|
Global markets, food prices & more...
Mirroring trends in the global markets, the Indian bourses were at the receiving end yesterday as markets shed 7% at the day's close. No surprises here as fears of a US recession continued to rage dragging the US indices and along with them the Asian and Indian indices as well. With the spectre of a recession in the US economy looming large, the US Fed's efforts to cut interest rates to prop up growth have failed to douse investor concerns. Higher food and crude prices have not helped matters either. While India has been considerably insulated from the subprime malaise, the country is nevertheless vulnerable to external shocks given that a large part of the surge in the stockmarkets as of late have been attributed to the FIIs. And this was amply demonstrated in yesterday's trading session when the weakness in the global markets spilled over to the Indian stock market. India's fundamentals continue to remain strong and even though a US recession will impact the former going forward to a certain extent, the growth pace is still expected to be higher than that reported by the developed and some of the developing nations.
As is the case with crude prices, food prices worldwide, including India, have been on an upward trend. According to World Bank, in 2007, prices for many staple foods reached record highs and global food reserves are at a 25-year low, making world food supply vulnerable to an international crisis or natural disasters. The increases have been attributed to the rising use of food crops for biofuels (given the firm oil prices), rapid income growth in developing countries, low stocks and droughts. To put things into perspective, US used 20% of its maize production for biofuels and since there was a shift of land from wheat to maize, wheat prices too shot up. Similarly, Brazil used 50% of its sugarcane for biofuels and Europe used 68% of its vegetable oil production (Source: World Bank). As a result the supply of these crops for food has been restricted leading to price increases. Looking ahead, population growth, lifestyle changes, use of crops to manufacture biofuels and climate change are likely to have an important bearing on food prices in the future.
Ranbaxy yesterday announced the settlement of its litigation suit with GlaxoSmithKline Plc for the latter's drug 'Imitrex'. This follows the company's initiatives to settle patent suits earlier with GSK Plc for 'Valrex' and Boehringer Ingelham for 'Flomax'. Dr.Reddy's had also taken a leaf out of Ranbaxy's book by settling with GSK Plc for 'Imitrex' as well last year. The biggest positive that can accrue to the challenging company by settling the patent suit outside the court is the certainty with respect to the exclusivity period, consequently enabling the challenging company to generate substantial revenues and profits. Also, given that patent challenges entail sizeable legal costs with no clear visibility in terms of revenues, out-of-court settlements mean that pending lawsuits get dropped obviating the need to incur more legal expenses. Besides this, the certainty of revenues from a particular drug gets more pronounced and the costs associated with legal matters no longer eat into the generic company's profitability. Thus, settling a patent challenge suit is a smart strategy if the risk-reward ratio is skewed towards the former.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 19, 2017
Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.
Aug 18, 2017
Buying the index now will hardly help make money in stocks even in ten years.
Aug 18, 2017
Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.
Aug 17, 2017
PersonalFN simplifies the mutual fund account statement for you.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407